The US Meals and Drug Administration (FDA) has instructed all GLP-1 drug-makers to replace their warning labels to incorporate the chance of great kidney damage that may end result from dehydration. This comes after individuals taking the treatment for both weight problems or diabetes have wanted to endure hemodialysis therapy.
The brand new warnings stem from GLP-1 customers reporting well being points to the FDA’s MedWatch, which displays for potential dangers that do not all the time current throughout medical trial phases. On this case, the reported critical kidney damage is not instantly brought on by taking a glucagon-like peptide-1 (GLP-1) receptor agonist drug, however the results of the dehydration – or “quantity loss” – that may end result from well-known gastrointestinal points together with vomiting, diarrhea and nausea. These signs are almost certainly to happen when the drug is began or when doses are elevated.
The FDA advises healthcare professionals to look out for indicators of renal operate decline in sufferers who’ve skilled ongoing gastrointestinal points that would result in dehydration.
The warnings shall be added to the labels of a spread of GLP-1 merchandise – Byetta, Bydureon BCISE, Mounjaro, Saxenda, Soliqua 100/33, Trulicity, Victoza and Xultophy 100/3.6 – whereas Ozempic, Rybelsus, Wegovy and Zepbound had already up to date their warnings.
The amendments come out of an abundance of warning, in an effort to forestall acute kidney damage requiring intensive blood-cleaning hemodialysis therapy. Dehydration causes lowered blood circulate to the kidneys (pre-renal AKI), which impairs the operate of the organ. If it isn’t flagged rapidly, it might result in somebody needing both momentary or ongoing hemodialysis.
Specialists advocate stopping GLP-1 treatment on the first signal of dehydration or kidney points – equivalent to darkish urine, rare urination and dizziness – and to hunt medical care. Whereas not frequent, these added warnings function a reminder that GLP-1 medication are potent drugs that require monitoring, particularly in weak sufferers.
The FDA additionally required another modifications to GLP-1 drug labels, together with making side-effect info extra uniform throughout completely different merchandise.
Apparently, GLP-1 medication have been heralded as an ally in combating kidney disease. In January, Ozempic (semaglutide) was granted FDA approval to deal with kidney illness sufferers, with the drug proven to assist preserve operate in declining kidneys.
Supply: FDA MedWatch through Med Shadow Foundation
